Day 2 of the SCTS
It's Day 2 of the Society for Cardiothoracic Surgery in GB & Ireland (SCTS) conference and we've been overwhelmed with all your interest in our Cold Plasma medical device, the SteriPlas. Visit us at booth 18 to learn more about how to bring the benefits of our medical device to your hospital.
How does the Adtec SteriPlas work so effectively?
Our patented cold plasma therapy utilises a physical mode of action approach delivered from an indirect microwave plasma source. Our cold argon plasma is an electrically charged and ionised gas that consists of charged particles, UV light and reactive oxygen and nitrogen species with the latter created as a by-product. They all work collectively to physically rupture the structure of bacteria even if they are protected within biofilm. Regardless of the type of bacteria, its resistance profile or whether they are Gram-positive or Gram-negative our cold plasma works quickly and effectively to destroy them. This has the leading advantage over conventional therapies such as antibiotics that rely on a chemical mode of action approach.
Although antibiotics have been a pivotal part of today’s medicine, they also contribute towards antimicrobial resistance rates particularly because bacteria can develop resistance such as those observed with diabetic foot ulcers that can often lead to amputations as a result.
However, as well as being fast-acting and effective, our cold plasma has shown that a primary or secondary resistance is unlikely to be developed due to its physical mode of action.
Mr Schlöglhofer to present SteriPlas at the ISHLT
Congratulations to Thomas Schlöglhofer from the Medical University of Vienna for his continued success of using our medical device to treat infections in LVAD patients. He will be presenting at The International Society for Heart and Lung Transplantation (ISHLT) conference in April to deliver the great results he has so far achieved.
His presentation, “Cold Atmospheric Plasma Therapy: A Powerful Tool for Treating Driveline Infections in Left Ventricular Assist Device Patients” will be during the “Bugs, Drugs, and Thugs: Fighting Infection in VADs Any Way We Can” Session on Wednesday 19th April between 5:30 PM - 6:30 PM.
We hope you will be there too to see him deliver his promising results.
For more information on how our medical device is fighting against multi resistant bacteria and biofilm in LVAD patients.
Today at The DGTHT Hermedizin 2023
It was a pleasure to see Dr Rotering’s presentation today at the DGTHT Hermedizin 2023 conference. His presentation on the SteriPlas for the treatment of deep sternal wound infections shows just how effective our Cold Plasma medical device is for the treatment of these chronic and deep wounds infected with biofilm.
Not only has the SteriPlas has shown to significantly decrease hospital bed occupancy, but it has shown to reduce mortality rates and prevent the need for expensive treatments by allowing sternal wall stability. The SteriPlas can successfully kill all forms of bacteria, regardless of their resistance profile or if they are protected within biofilm.
SteriPlas heals wounds quickly
Did you catch the leading Serbian media newspaper, Večernje Novosti, last week? Our SteriPlas was featured in the article, “Cold plasma heals wounds quickly” composed by Dr Zorić.
Dr Zoric has been using our cold plasma medical device to treat hard-to-heal and stalled wounds infected with biofilm. These problematic wounds have responded very well with our SteriPlas treatment and patients have been healed that were otherwise stalled by conventional therapies.
If you are within Serbia and interested to learn more about our medical device, contact our medical distributor Borf Health Care on info@borf.biz for more information.
Advanced Wound Care Summit Europe 2022
It was an honour to present at the Advanced Wound Care Summit Europe conference this week. Our extensive knowledge and library of clinical trials and our history as the experienced leader of Cold Plasma medicine was presented to the audience to bring light to the positive benefits of Adtec Cold Plasma devices.
If you would like to hear more about our efficacy and strengths for wounds, surgical site infections and medical dermatology, send us a PM or email us at info@adtecplasma.com
Presenting at The Advanced Wound Care Summit Europe
We’re looking forward to the Advanced Wound Care Summit Europe conference. On the 13th December, our Managing Director, Mary McGovern, will be presenting “Cold Plasma Medicine – Clinical Trials and Regulatory Challenges” where she will explain the importance of clinical trials to test the safety and efficacy of a medical device and the challenges that one can expect.
Since we were the first company worldwide to introduce cold plasma treatment on wounds in clinical trials, it comes to no surprise that we have good experience in this field. Adtec Healthcare boasts a wide collection of clinical trials and studies of our SteriPlas cold plasma medical device to authenticate the efficacy, safety and no side effects claims that we state. We have proven clinical efficacy of managing infections in diabetic foot ulcers and surgical site infections where other treatments have failed.
Evident to our success, this is why Adtec Healthcare’s clinical trials and studies are often referenced by other cold plasma manufacturers who do not have their own clinical studies. With patient safety in mind, clinical trials proving the efficacy must be completed by each manufacturer for the technology used in their device.
New Wound Management of Driveline Infections with Cold Atmospheric Plasma
We’re ecstatic to see Dr Jamila Kremer’s publication, “New Wound Management of Driveline Infections with Cold Atmospheric Plasma” is now live for public viewing. The paper can be viewed here: https://doi.org/10.3390/jcdd9110405.
The use of our Adtec cold plasma medical device has greatly benefitted her LVAD infection patients treated at the University Heidelberg Hospital since 2019. The results stipulate a stronger infection management advantage over conventional therapy alone for LVAD infections. This is coupled with the benefit of our cold plasma being safe, painless, contact-free and free from side effects.
Driveline infections are the most prevalent infections and reported in up to 60% of LVAD patient cases. Infection of the LVAD system is the fourth most common cause of death within one year after implantation. Dr Kremer’s publication documents Adtec cold plasma treated patients showed a 100% survival rate.
For more information about the benefits of our Cold Plasma medical device, contact us at info@adtecplasma.com
Poster presentation at the DFSG 2022
Did you see Dr Pierides' poster presentation yesterday at the DFSG Diabetic Foot Study Group conference? The poster featured the Adtec SteriPlas success in treating chronic infected diabetic foot ulcers.
The SteriPlas replaced the use of antibiotics for these heavily infected and impacted wounds and had shown remarkable success.
Adtec at the Diabetic Foot Study Group conference in Bratislava
Don't forget to visit us at the Diabetic Foot Study Group (DFSG) conference this weekend. We're having a great time welcoming you to our booth. Our SteriPlas is here ready to give you a live demonstration on how easy it is to use.
